Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Lung Neoplasms 2Stroke 1Sarcoma 1Pulmonary Disease, Chronic Obstructive 1Prostatic Neoplasms 1Primary Myelofibrosis 1Polycythemia Vera 1Platinum-Refractory Fallopian Tube Carcinoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Microsatellite Instability 1Lymphoma 1Kidney Failure, Chronic 1Diabetes Mellitus 1Coronary Artery Disease 1Carcinoma, Non-Small-Cell Lung 1COVID-19 1Breast Neoplasms 1

Interventions

Peripheral Blood Stem Cell Transplantation 3fludarabine phosphate 2Whole-Body Irradiation 2Tacrolimus 2Pentetic Acid 2Methotrexate 2Decitabine 2Cyclosporins 2Cyclosporine 2Busulfan 2spartalizumab 1siltuximab 1sabatolimab 1ruxolitinib 1pelcitoclax 1merphos 1ethanolamine oleate 1durvalumab 1Trimethoprim, Sulfamethoxazole Drug Combination 1Trimethoprim 1Therapeutics 1Sulfamethoxazole 1Sodium Chloride 1Saline Solution, Hypertonic 1Saline Solution 1Psychiatric Rehabilitation 1Pentostatin 1Ondansetron 1NIS-793 1Mycophenolic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Primary Myelofibrosis × Disulfides × Clear all
NCT02871323 2019-08-20

Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

Northwestern University

Phase 1 Withdrawn
Myeloid

Polycythemia Vera, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡